Stocks of Novavax, Inc (NASDAQ:NVAX) traded higher last session on Wall Street, up 7.71% to $8.94.
NVAX stock price is now -11.31% away from the 50-day moving average and -13.49% away from the 200-day moving average. The market capitalization of the company currently stands at $1.54B.
With the price target maintained at $8, JP Morgan recently Downgraded its rating from Neutral to Underweight for Novavax, Inc (NASDAQ: NVAX). , while ‘BofA Securities’ rates the stock as ‘Neutral’
In other news, Dubovsky Filip, Officer bought 7,335 shares of the company’s stock on Sep 18 ’24. The stock was bought for $95,331 at an average price of $13.00. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 21 ’24, Director YOUNG JAMES F sold 7,500 shares of the business’s stock. A total of $105,675 was realized by selling the stock at an average price of $14.09. This leaves the insider owning 61,760 shares of the company worth $0.55 million. A total of 4.47% of the company’s stock is owned by insiders.
During the past 12 months, Novavax, Inc has had a low of $3.53 and a high of $23.86. The fifty day moving average price for NVAX is $10.08 and a two-hundred day moving average price translates $10.33375 for the stock.
The latest earnings results from Novavax, Inc (NASDAQ: NVAX) was released for 2024-09-30. The company reported revenue of $84.51 million for the quarter, compared to $186.99 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -54.8 percent.
